CLINICAL_TRIALS
trial_result
· 2023-12-06
Clinical Trial Update: Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy [Phase 2]
Summary
Phase 2 trial evaluating crizotinib in high-risk uveal melanoma after definitive therapy has completed and results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Columbia University | Conditions: Uveal Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2023-12-06